Literature DB >> 33411775

A study of evaluating specific tissue oxygen saturation values of gastrointestinal tumors by removing adherent substances in oxygen saturation imaging.

Keiichiro Nishihara1, Keisuke Hori1, Takaaki Saito2, Toshihiko Omori3, Hironori Sunakawa1, Tatsunori Minamide1, Masayuki Suyama1, Yoichi Yamamoto1, Yusuke Yoda1, Kensuke Shinmura1, Hiroaki Ikematsu1, Tomonori Yano1.   

Abstract

OBJECTIVES: Oxygen saturation (OS) imaging is a new method of endoscopic imaging that has clinical applications in oncology which can directly measure tissue oxygen saturation (Sto2) of the surface of gastrointestinal tract without any additional drugs or devices. This imaging technology is expected to contribute to research into cancer biology which leads to clinical benefit such as prediction to efficacy of chemotherapy or radiotherapy. However, adherent substances on tumors such as blood and white coating, pose a challenge for accurate measurements of the StO2 values in tumors. The aim of this study was to develop algorithms for discriminating between the tumors and their adherent substances, and to investigate whether it is possible to evaluate the tumor specific StO2 values excluding adherent substances during OS imaging.
METHODS: We plotted areas of tumors and their adherent substances using white-light images of 50 upper digestive tumors: blood (68 plots); reddish tumor (83 plots); white coating (89 plots); and whitish tumor (79 plots). Scatter diagrams and discriminating algorithms using spectrum signal intensity values were constructed and verified using validation datasets. StO2 values were compared between the tumors and tumor adherent substances using OS images of gastrointestinal tumors.
RESULTS: The discriminating algorithms and their accuracy rates (AR) were as follows: blood vs. reddish tumor: Y> - 4.90X+7.13 (AR: 95.9%) and white coating vs. whitish tumor: Y< -0.52X+0.17 (AR: 96.0%). The StO2 values (median, [range]) were as follows: blood, 79.3% [37.8%-100.0%]; reddish tumor, 74.5% [62.0%-86.9%]; white coating, 73.8% [42.1%-100.0%]; and whitish tumor, 65.7% [53.0%-76.3%].
CONCLUSIONS: OS imaging is strongly influenced by adherent substances for evaluating the specific StO2 value of tumors; therefore, it is important to eliminate the information of adherent substances for clinical application of OS imaging.

Entities:  

Year:  2021        PMID: 33411775      PMCID: PMC7790263          DOI: 10.1371/journal.pone.0243165

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  30 in total

1.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Authors:  Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Magnified endoscopic observation of small depressed gastric lesions using linked color imaging with indigo carmine dye.

Authors:  Yoshiyasu Kitagawa; Taro Hara; Dai Ikebe; Rino Nankinzan; Hideyuki Takashiro; Ryosuke Kobayashi; Kazuyoshi Nakamura; Taketo Yamaguchi; Takuto Suzuki
Journal:  Endoscopy       Date:  2017-09-27       Impact factor: 10.093

3.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Authors:  Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André
Journal:  Lancet Oncol       Date:  2017-07-19       Impact factor: 41.316

4.  Diagnostic value of blue laser imaging combined with magnifying endoscopy for precancerous and early gastric cancer lesions.

Authors:  Yang Zhenming; Shen Lei
Journal:  Turk J Gastroenterol       Date:  2019-06       Impact factor: 1.852

5.  Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.

Authors:  Sven De Bruycker; Christel Vangestel; Tim Van den Wyngaert; Leonie Wyffels; An Wouters; Patrick Pauwels; Steven Staelens; Sigrid Stroobants
Journal:  Mol Imaging Biol       Date:  2016-08       Impact factor: 3.488

6.  NIH Image to ImageJ: 25 years of image analysis.

Authors:  Caroline A Schneider; Wayne S Rasband; Kevin W Eliceiri
Journal:  Nat Methods       Date:  2012-07       Impact factor: 28.547

Review 7.  Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland.

Authors:  H B Stone; J M Brown; T L Phillips; R M Sutherland
Journal:  Radiat Res       Date:  1993-12       Impact factor: 2.841

8.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

9.  Hypoxia‑induced expression of CXCR4 favors trophoblast cell migration and invasion via the activation of HIF‑1α.

Authors:  Zhan Zhang; Pengyun Li; Yan Wang; Huan Yan
Journal:  Int J Mol Med       Date:  2018-05-22       Impact factor: 4.101

10.  Lysyl oxidase and hypoxia-inducible factor 1α: biomarkers of gastric cancer.

Authors:  Ya-Lin Han; Li Chen; Rui Qin; Guan-Qing Wang; Xiao-Hua Lin; Guang-Hai Dai
Journal:  World J Gastroenterol       Date:  2019-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.